<DOC>
	<DOC>NCT02537379</DOC>
	<brief_summary>This post-marketing surveillance (PMS) study for Sovaldi速 tablets (sofosbuvir, SOF) administered in combination with Copegus速 tablets (ribavirin, COPE) will evaluate the safety and efficacy of SOF administered in combination with ribavirin under real world use in Japan. Among adult patients with chronic genotype 2 hepatitis C virus (HCV) infection and treated with SOF+ribavirin in routine clinical use, the primary objective of this study is to evaluate the incidence of adverse drug reactions (ADRs) under real world settings.</brief_summary>
	<brief_title>Use-Results Surveillance Study of Sovaldi速 Plus Copegus速 in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key Adult patients with serogroup 2 (genotype 2) chronic HCV infection with or without compensated cirrhosis Patients who are prescribed SOF+COPE Key Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hepatitis C virus</keyword>
	<keyword>observational</keyword>
	<keyword>post-marketing</keyword>
	<keyword>sofosbuvir</keyword>
</DOC>